Grizzle had the pleasure of sitting down with the CEO of MindMed – JR Rahn.

Terry Chong leads an in-depth and insightful interview with JR, Terry is a veteran pharmaceutical / biotech investor and a partner at Grizzle Ventures.

JR provides a great primer about the evolution of psychedelic research and mental health and how MindMed is pioneering treatments in the emerging medical applications.


About Author

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.